HIV Treatment Cuts Biological Aging by 4 Years: A Revolutionary Discovery
The recent study presented at ESCMID Global 2026 has revealed a groundbreaking finding in the field of HIV treatment and aging research. The study, conducted by Dr. Barry Ryan and his team, has shown that antiretroviral therapy (ART) significantly reduces accelerated biological aging in people with HIV (PWH) by nearly four years. This discovery has the potential to revolutionize how clinicians monitor HIV treatment and long-term health outcomes, offering new hope for those living with the virus.
The research team developed a plasma proteomic aging clock (PAC) to estimate biological age, reflecting physiological aging rather than chronological age. This tool was applied to participants in the Swiss HIV Cohort Study (SHCS), a unique group that had samples collected for up to eight years before starting ART. The PAC was trained on 941 plasma samples from PWH receiving successful ART and then evaluated in an independent cohort of 80 participants.
The results were remarkable. During untreated HIV infection, the PAC estimated that participants' biological age was accelerated by a median of 10 years. However, after a median duration of 1.55 years of ART, researchers observed a statistically significant mean reduction of 3.7 years in proteomic age. This finding suggests that ART not only suppresses the virus but also actively reverses the accelerated aging process.
Dr. Ryan's commentary highlights the importance of early start and optimal adherence to ART. He emphasizes that the study's unique group, with samples collected before ART, allowed them to measure the effect of untreated HIV infection and successful ART on various aging markers. In each case, they found that uncontrolled HIV infection is linked to faster aging, and ART significantly slows this process.
The PAC primarily captures changes in inflammatory signaling and drug metabolomic pathways. When compared with the team's previously published epigenetic aging clock (EAC), both clocks showed similar overall trends. However, the PAC was more sensitive to short-term immune changes, demonstrating a faster increase during untreated infection and a more rapid decline once HIV in the blood was suppressed with ART.
Interestingly, the reversal of proteomic age acceleration after ART was not significantly associated with CD4+ or CD8+ T-cell count recovery. This suggests that the reversal reflects broader inflammatory and innate immune remodeling rather than T-cell reconstitution alone. Dr. Ryan explains that the participants were closely monitored pre-ART, including CD4 and CD8 T-cell counts, but accelerated proteomic aging was observed irrespective of T-cell homeostasis.
The authors call for external validation of the PAC in more diverse global populations and for proteome-wide feature attribution studies to pinpoint the specific pathways driving HIV-related aging biology. Dr. Ryan believes that while specific pathways of reversal may vary by ancestry and population, the global trend of accelerated aging with untreated HIV and its attenuation after virological suppression is likely to generalize.
This study raises important questions about the broader implications of HIV treatment on aging and long-term health. It highlights the need for early intervention and optimal adherence to ART, not only to suppress the virus but also to potentially slow down the aging process. As Dr. Ryan concludes, "This research demonstrates the importance of early start and optimal adherence to ART, and it opens up new avenues for further exploration in the field of HIV treatment and aging."
In my opinion, this study is a significant breakthrough in our understanding of HIV treatment and its impact on aging. It challenges the traditional view of HIV as a chronic condition and suggests that ART may have broader implications for slowing down the aging process. This finding has the potential to transform the way we approach HIV care and could lead to new strategies for promoting healthier aging in people living with HIV.
